Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 13, 2024 1:59pm
97 Views
Post# 35930991

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaMarch 13, 2024 - WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down.
 
It’s hard to disentangle WuXi AppTec’s rise from China’s. Over the last two decades, the Shanghai-based company grew from nothing into a research superstore for the world’s biopharma companies.

https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre-not-ready-if-the-us-cracks-down/


March 6 (Reuters) - The U.S. Senate's homeland security committee voted on Wednesday to approve a bill that could restrict business with Chinese biotech companies like BGI and WuXi AppTec on security grounds. The bill is designed to keep Americans' personal health and genetic information from foreign adversaries. WuXi AppTec, for example, generates more than half of its sales from its U.S. business and operates facilities across the country including in Georgia, Pennsylvania and California, as well as a new campus set to open in Delaware., opens new t on national security grounds.The bill is designed to keep Americans' personal health and genetic information from foreign adversaries. The bill has spurred deep concern among investors, driving a sell-off in the shares of WuXi AppTec when news of its introduction first reached Chinese markets last month.

<< Previous
Bullboard Posts
Next >>